Cerus Corporation delivered solid third-quarter performance, continuing its momentum with significant growth in INTERCEPT adoption and steady advancements in both clinical development and operational execution.

• INTERCEPT adoption in the U.S. has risen to approximately 60%, with potential to exceed 80% as the product's value proposition improves.
• Recent selection by the German Red Cross for a key study reinforces INTERCEPT's growing acceptance as the standard of care in platelet treatments.
• Cerus completed enrollment for the Phase III RedeS trial in the U.S. for red blood cells, anticipating crucial results in 2026.
• Continued focus on achieving positive non-GAAP adjusted EBITDA for the full year 2025, highlighting operational efficiency.
• Planned PMA submission for the next-generation LED-based INT200 device is on track for mid-2026, aiming to enhance platelet shelf life.